telatinib

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Multidrug resistance (MDR) is a phenomenon where cancer cells become simultaneously resistant to anticancer drugs with different… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2011
2011
BACKGROUND Blocking both receptor and ligand of the vascular endothelial growth factor (receptor) VEGF(R) pathway might be… (More)
Is this relevant?
2011
2011
Geldanamycin and its derivative 17AAG [17-(Allylamino)-17-demethoxygeldanamycin, telatinib] bind selectively to the Hsp90… (More)
Is this relevant?
2011
2011
4122 Background: Angiogenesis is essential for tumor growth and plays an important role in metastasis in gastrointestinal (GI… (More)
  • figure 4
Is this relevant?
Review
2011
Review
2011
81 Background: Response to the antiangiogenic agent, bevacizumab, by CT has been associated with a unique morphologic change in… (More)
Is this relevant?
2010
2010
PURPOSE We studied the safety and tolerability of telatinib, an orally available, small-molecule tyrosine kinase inhibitor of the… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2009
2009
Purpose Telatinib is an orally active small-molecule tyrosine kinase inhibitor of kinase insert domain receptor (KDR; VEGFR-2… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2009
2009
PURPOSE Telatinib (BAY 57-9352) is an orally available tyrosine kinase inhibitor of vascular endothelial growth factor receptor… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Hypertension is a commonly reported side effect in antiangiogenic therapy. We investigated the hypothesis that telatinib… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2008
2008
Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?